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Monozygotic (MZ) and dizygotic (DZ) twins participate in research to partition variance in 
health, disease and behavior into genetic and environmental components. However, there are 
other innovative roles for twins in medical research. One such way is involving MZ and/or DZ 
twins concordant for a specific phenotype, in a co-twin control designed randomised controlled 
trial (RCT). This provides the most effective way to control for confounding factors, as one 
twin from each pair receives the intervention and the other twin acts as their control. To our 
knowledge, no reviews have been conducted that summarize the involvement of twins in RCTs. 
Therefore, we conducted a systematic literature search using the USA Clinical Trials Database, 
NHS electronic databases, MEDLINE, EMBASE, and PsychINFO for RCTs that involved MZ 
and/or DZ twins as clinical trial participants. From 1598 articles, 50 peer-reviewed English 
language publications met our pre-defined inclusion criteria. Sample sizes for RCTs ranged 
from a total number of participants 2 to 1162; however, 32 (64 %) studies had a sample size of 
100 or less, and of those 12 (24%) had less than ten.  
Both MZ and DZ twins have been recruited to the RCTs. In most instances (33/50) each twin 
from a pair were assigned to different study arms. Most of those studies (24/33) included MZ 
twins only.   
Despite the methodological advantages, the use of MZ and DZ twins as participants in 
interventional RCTs appeared limited. We discuss the issue of different ways of randomizing 
twins and the implications for sample size and power. The use of twin registries and 
international collaborations is discussed as a way to facilitate larger sample size trials and best 







Twins studies are best known for using the classical twin design, based on comparisons 
between the similarity of monozygotic (MZ, identical) and dizygotic (DZ, fraternal) twins to 
partition the variance in health, disease and behaviour into genetic and environmental 
components, predominantly using observational study designs (Boomsma et al., 2002,  van 
Dongen et al., 2012)  
Studies involving twins have become increasingly relevant due to the continuous work 
of twin registries and studies that have, collectively, amassed data and biological material on 
hundreds of thousands of twins, and have provided a valuable resource for studying complex 
genetic phenotypes and their underlying biology (Hur & Craig, 2013). The availability of 
longitudinal data through the International Society of Twin Studies and International Network 
of Twin Registries (INTR) is also proving to be a valuable resource, not only for new studies 
but also for global collaborations (Buchwald et al., 2014). Data derived from a collaboration 
of 54 international twin cohort databases participating in the CODATwins Project is a prime 
example (Jelenkovic et al., 2015, 2016; K. Silventoinen et al., 2015; Karri Silventoinen et al., 
2016; Yokoyama et al., 2016). 
Within-pair comparisons of phenotypically-discordant MZ and DZ twin pairs through 
an observational co-twin controlled design can illuminate the non-shared environmental 
differences influencing human traits. However, such comparisons are arguably more efficient 
in intervention co-twin control studies using phenotypically-concordant pairs, where one twin 
is randomly assigned to receive the intervention and the other twin acts as their control. A 
comparison between the co-twin control design in intervention and non-intervention studies, 
along with other novel utilities of this design have been discussed in detail previously (Plomin 
& Haworth, 2010). 
The term “intervention” refers broadly to any clinical manoeuvre offered to study 
participants that may have an effect on their health status (Jadad, A.R, 1998).  Randomised 
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controlled trials (RCTs) are considered the gold standard for testing interventions and ‘the most 
rigorous way of determining whether a cause-effect relationship exists between treatment and 
outcome and for assessing the cost effectiveness of a treatment’ (Sibbald & Roland, 1998).  
Random allocation provides participants the same chance of being assigned to each of the 
treatment groups (Altman DG, 1991). The purpose of random allocation is to ensure that the 
characteristics of participants are as similar as possible across treatment groups prior to the 
initiation of an intervention (baseline). If randomization is done properly, it reduces the risk of 
a serious imbalance in known and unknown factors that could influence the clinical course of 
the participants. Therefore, any significant differences between treatment groups in the 
outcome of interest can be attributed to the intervention and not to any unidentified factor(s). 
However, involving MZ twins in a co-twin control designed RCT has advantages over 
the traditional RCT involving unrelated individuals. The co-twin control design can provide 
perfect control for many of the potential confounding factors that could be imbalanced between 
treatment groups by chance, especially genetic makeup due to matching.  Confounding poses 
a considerable threat to the validity of studies aiming to identify causal mechanisms, creating 
spurious associations. Confounders can be either measured, and thereby statistically controlled, 
or unmeasured. The latter introduces the greatest problems for causal inference. Genetic 
confounding of identified associations is often a very real possibility but is frequently 
overlooked by researchers. There is also the possibility of unmeasured environmental 
confounding, occurring when there are one or more contextual factors that affect both the 
exposure and the outcome. Twin samples allow generalizable assessments of associations and 
the ability to evaluate the extent of both genetic and environmental confounding; one of the 




DZ twins may also allow for matching due to shared environment as well as some 
genetic component and age, which can potentially justify the choice for recruiting DZ twins 
rather than siblings for a study. However, challenges such as teasing out individual factors in 
the context of complex interacting contributors may arise when using DZ twins in RCTs. It is 
also believed that the co-twin control RCT approach will have the additional advantage of 
requiring a relatively smaller sample size without reducing the statistical power (Plomin & 
Haworth, 2010). However, if twins from the same pair are randomly assigned to the same 
treatment group or independently of each other, rather than to different treatment groups as in 
the co-twin control design, the benefits in sample size for an RCT involving twins may be lost 
(Yelland et al, 2017). Intervention studies involving twins do exist in the literature. One such 
trial testing the effect of Vitamin C intake on common cold symptoms found that the relative 
power of this design compared to an unpaired design could be 2 to 14 times stronger, which 
means an unpaired study design would require much larger sample sizes to detect the same 
effect (Carr et al., 1981; Martin et al., 1982). 
However, in our opinion the full advantages and the rationale for involving twins in 
RCTs have not been adequately discussed or explored. Therefore, we carried out this review 
as the first step to identify studies using twins as participants for RCTs. In-depth analyses of 
the quality of individual studies and methodological issues of these studies or meta-analysis 
was not an aim of this review. Instead, we aimed to identify all published material including 
RCTs involving only twins as participants up until 2015 using the selection criteria described 
below, and to summarise basic trial characteristics including sample size, inclusion criteria, 
whether trials include only MZ, DZ or both, and randomisation method (i.e., whether same pair 
twins were randomly assigned to the same treatment group independent of each other, or to 




Materials and Methods 
A comprehensive search was carried out using the following databases: USA clinical trial 
(https://clinicaltrials.gov/), MEDLINE (1946 - 2015), EMBASE (1974 - 2015) and PsychINFO 
(1806 - 2015). We also performed an extensive search using PubMed (all publications until 
March 2015). Searches were confined to articles in English.  
In the NHS library electronic database searches (MEDLINE, EMBASE and PsychINFO), the 
search term “twins”, “randomi*, “control*” “trial*”with Boolean operator AND was used in 
“title and abstract”. Each database was searched individually using the search terms. This 
allowed for all alternative spelling (randomised and randomized), variations of control (control, 
controls and controlled) and singular or pleural trial (trial and trials) to be searched 
simultaneously. The search terms used for the PubMed search also took all of used these 
variations into account (as per the NHS library search).  
 
Data extraction 
Data was extracted by one reviewer (DG), and then checked independently by a second 
reviewer (AS). All publications identified in the searches were searched for duplicates. 
Eligibility for inclusion in the review was decided by DG and AS. Full versions of publications 
selected were obtained and reviewed independently by three authors (AS, DG, and TS). Any 
discrepancy in judgements was resolved through consensus. Abstracts eligible for inclusion 
were confined to those reporting on a RCT that had used only twins as study participants but 
not mothers pregnant with twins. Information was extracted from each of the studies relating 
to authors, study location, database, twin registry (if any), condition, primary outcome, sample 
size, eligible age, eligible sex, zygosity, twin assignment (same treatment groups, different 





USA clinical trial database 
The initial search using the USA clinical trial database resulted in a total of 90 clinical trials.  
Of these, 50 studies were registered with twins as study participants, and 40 studies were 
registered with mothers who were pregnant with twins as study participants. Of the 90 twin 
studies, there were 29 RCTs.  Of these, 23 had used mothers pregnant with twins as the study 
participants and only six studies had recruited twins as the study participants (Figure 1).  
<INSERT Figure 1 here> 
Extended search using other databases 
After taking into account all duplicates and discounting papers including mothers pregnant 
with twins, the NHS library searches gave a total of 51 papers on RCTs using twins as study 
participants; 47 from MEDLINE, and a further 4 papers not found in MEDLINE were found 
in EMBASE. No additional papers were found in PsychINFO.  
PubMed searches gave additional 8 papers using twins as study participants that were not 
found in either the MEDLINE or EMBASE search. The search term “Twins and Randomized 
Control Trial” found two papers, the terms “Twins and Randomised Controlled Trial” found 
five, the term “Twins and Randomised Control Trials” found one. The search terms “Twins 
and Randomised Controlled Trial” and “Twins and Randomised controlled trials” gave the 
exact same result when substituting the ‘s’ for a ‘z’ in the word ‘randomised’. The full text of 
all 59 potentially relevant papers were examined in more detail, and 50 were consistent with 
the inclusion criteria for this review (Figure 2). 
<INSERT Figure 2 here> 
Trial Characteristics 
Sample size and allocation of twins 
8 
 
The sample size varied greatly across the RCTs included in the review. Table 1 illustrates that 
42% of RCTs had a sample size which fell within 10-100 twin pairs. Twenty four percent of 
the studies had a sample size smaller than 10 twin pairs as research participants. Therefore, 
the majority of studies had 100 twin pairs or less as participants. 
<INSERT Table 1 here> 
Zygosity and twin assignment across the randomised controlled trials 
As illustrated in Table 1, 13 RCTs assigned both twin in a pair to the same study arm, 10 of 
which included both MZ and DZ twins, two included only MZ twins and one included only 
DZ twins. This is in contrast to 33 RCTs where twin pairs were assigned to different study 
arms, of which 6 included both MZ and DZ twins, 24 included only MZ twins and 3 included 
only DZ twins.  In most instances (33/50) the pair of twins had been assigned to different 
study arms, and most of these studies (24/33) had been with MZ twins.   
 
Location of studies 
The vast majority of the studies included in this review were conducted in the USA (21). The 
remaining studies were from Canada (5), Australia (3), UK (3), Finland (2), Germany (2), 
Greece (2), and one from each of the following countries; Bangladesh,  Belgium , Dominican 
Republic , France , Hawaii , Hong Kong , India , Iran , Norway , Switzerland , Taiwan  and 
Thailand . 
A twin registry had been used to support recruitment in 8 of the RCTs. These were the 
Australian Twin Registry (3), the Twin Research Registry, UK (3), the St Thomas UK Adult 
Twin Registry (1), and the University of Washington Twin Registry (1). In the remaining 39 
studies, there was no evidence of a twin registry being used to support recruitment. RCTs were 
diverse in nature and areas included preterm birth nutrition, behaviour, dental health, antiviral 





Randomised controlled trials involving only twins as participants are limited, as shown by this 
review. Only 50 studies met our inclusion criteria after a comprehensive search in clinical trials 
and NHS library databases, even across a wide range of disciplines. Out of the 186,027 clinical 
trials registered in the USA clinical trial register, only 6 RCTs used twins as participants. While 
it is impossible to determine how many twin RCTs had been reported through PubMed and 
other data bases, it is clear that it is disproportionate to the number involving singletons. 
Therefore, it can be concluded that specifically using twins in RCTs is not common compared 
to using singletons. 
Randomisation of twins in a RCT 
When twins participate in a clinical trial, they may be randomised to the same treatment group, 
independent of each other, or to different treatment groups as in the co-twin control design. 
Our review found that most clinical trials used the co-twin control design with MZ twins.  
Therefore, it could be concluded that in the majority of studies, MZ twins had been used for 
perfect control of genetic variation between the treatment groups. Recent work suggests that 
twins and their parents have a strong preference for assigning both twins to the same treatment 
group, rather than using the co-twin control design (Bernardo, Nowacki, Martin, Fanaroff, & 
Hibbs, 2015). This has important implications for future RCTs conducted in twins, since 
recruitment may be more successful if both twins in a pair will receive the same treatment, 
although the impact of different methods of randomising twins on the sample size must also be 
considered. 
 
The impact of twins on sample size and power  
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The sample size of trials included in our review ranged from 2 to 1162 (table 1) and in the 
majority of trials (64%), the sample size was 100 or less. Although we did not attempt to 
assess whether the sample size was adequate for addressing the specific research question of 
each trial, this does raise the issue of whether small RCTs involving twins are adequately 
powered to detect meaningful treatment effects. One of the advantages of conducting RCTs 
in twins is that the sample sizes can be less compared to using non-twin RCTs (Miller et al., 
1995; Carr et al., 1981; Martin et al., 1982). However, this will depend on how twins from 
the same pair are randomised.  If the co-twin control design is used, such that one twin from 
each pair receives the intervention and the other acts as their control, the trial will have more 
power than a trial in singletons, and hence the sample size can be reduced. In contrast, if both 
twins are assigned to the same treatment group, the trial will have less power than a trial in 
singletons, thus requiring a larger sample size.  This is due to the fact that comparisons of the 
intervention and control conditions must be made across twin pairs, rather than within twin 
pairs as in the co-twin control design. If twins from the same pair are randomised 
independently (ignoring that they are twins and treating as individuals), the trial will likely 
have similar power to a trial in singletons. Methods for calculating the sample size for trials 
involving twins only or a combination of singletons and twins have been discussed elsewhere 
(Yelland et al, 2017). 
International collaborations using twin registries  
We found that only 11/50 (22%) of the studies used twin registries for recruitment. One option 
particularly for multi-centre RCTs with a relatively large sample size is international 
collaboration, as currently utilised in non RCT twin research (Buchwald et al., 2014). CODA 
Twins project was a classic example initiated in 2013 by identifying all twin projects in the 
world. It comprises 67 twin projects having data from both monozygotic (MZ) and dizygotic 
(DZ) twin pairs. The main sources used to identify the projects were a special issue of Twin 
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Research and Human Genetics (Hur and Craig 2013), and the participants of the International 
network of twin registries consortium (INTR) (Buchwald et al. 2014, van Dongen et al. 2012). 
The INTR is a platform for international collaborations, and would be an excellent resource for 
large scale multi-centre clinical trials.  
Implications for future work and directions  
To understand the potential benefits of the co-twin control design, it would be useful to 
compare the sample sizes of twin RCTs and non-twin RCTs required to detect the same effect 
size.  The advantages and disadvantages of inclusion of both MZ and DZ twins in RCTs 
needs more in-depth discussion and are areas for future methodological research. 
Contamination between intervention and control twin participants allocated to different 
treatment groups (particularly in psychological interventions) especially among twins living 
together will be an important issue to address. 
 
Limitation of the review 
In-depth analyses of the quality of individual fifty studies qualified for the review and 
methodological issues of these studies were not done. We did not include a meta-analysis for 
this review.  
 
Conclusion 
Both MZ and DZ twins have been used in RCTs. However, on a majority of instances they 
have been MZ twins randomised to opposite arms of a RCT.  
The continuous development and implementation of innovative twin designs in intervention 
studies, especially RCTs, indicates that twin research can extend beyond the more widely 
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Figure 1:  PRISMA diagram to illustrate the literature search process and the resulting 
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Figure 2: PRISMA diagram to illustrate the literature search process and the 
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Table 1: Characteristics of randomised controlled trials with twin participants. 
Characteristic  Number (Percentage) of Trials (n=50)  
Number of participants recruited  
    <10 12 (24) 
    10-100 21 (42) 
    101-250 14 (28) 
    >250 3 ( 6) 
Sex 
 
    Males only 
    Females only 
7 
9 
    Males and females 34 
Zygosity 
 
    MZ only 27 (54) 
    DZ only 4 (8) 
    MZ and DZ 19 (38) 
Twin assignment 
 
    Same treatment groups 13 (26) 
    Different treatment groups 33 (66) 
    Independent allocation 3 (6) 
    Unclear 1 (2) 
Location 
 
    United States 21 (42) 
Canada 5 (10) 
Europe 10 (20) 
LMIC 2 (4) 
Other 12 (24) 
Twin recruitment method  
Twin registry 8 (16) 
Other 42 (84%) 
  
